|Printable version||E-mail this to a friend|
EMA Workshop: working towards new therapies for spinal muscular atrophy
The event will be broadcast live on 11 November
The European Medicines Agency (EMA), Spinal muscular atrophy (SMA) Europe and the TREAT-Neuromuscular diseases (NMD) network are holding a one-day workshop to discuss, support and advance the development of therapies for the treatment of spinal muscular atrophy (SMA). SMA Europe and TREAT-NMD network are two non-profit organisations that bring together patients and academics from Europe and beyond to progress research into SMA and facilitate the development of new therapies.
The workshop will take place at EMA’s premises in London on 11 November 2016, starting at 09:00.
SMA is a rare genetic disease that affects the control of muscle movement. It is caused by a loss of specialised nerve cells, called motor neurons, which results in weakness and wasting (atrophy) of muscles used for activities such as crawling, walking, sitting up, and controlling head movement. Children born with the most serious form of the disease rarely survive beyond the age of two because of severe breathing problems.
At present there is no cure for SMA. Available treatments focus on managing symptoms and preventing complications. However, new therapies are currently being developed and SMA might become one of the first inherited neurological diseases to be successfully treated. A number of experimental therapies are currently being evaluated in early clinical trials and EMA has provided scientific advice to medicine developers on the appropriate tests and studies to be used in the development of medicines for SMA a number of times in the past few years.
The workshop will convene key stakeholders – patients, doctors, industry representatives, researchers and regulators – to take stock of the latest scientific developments in the area and discuss ways of developing therapies for the treatment of SMA. Topics for discussion will include an overview of the disease, the pharmacology of the molecules under investigation, natural history data, clinical outcome measures and potential use of biomarkers in drug development.
- Agenda - EMA - Spinal muscular atrophy workshop (07/11/2016)
Latest News from
EFSA reinforces independence policy22/06/2017 16:16:00
The EFSA has a robust, well-balanced independence policy, its Management Board said after approving a number of new measures to further strengthen the Authority’s impartiality and protection against improper influence.
Romania, UK, Belgium & Switzerland – coordinated takedown of a Romanian THB criminal network22/06/2017 15:20:00
On 19 June, Romanian prosecutors from the Directorate for the Investigation of Organised Crime and Terrorism (DIICOT), Piteşti Territorial Service, together with judicial police officers from the organised crime fighting structures within Piteşti, Craiova, Ploiesti, Bucharest, Vâlcea and Dâmboviţa, carried out 71 house searches in Romania.
Solidarity with Italy: €1.2 billion of EU funds to support reconstruction works after the earthquakes22/06/2017 14:10:00
The EC proposes to mobilise €1.2bn under the EU Solidarity Fund, the highest sum ever mobilised in a single instalment, following the earthquakes of 2016 and 2017 in the Italian regions of Abruzzo, Lazio, Marche and Umbria.
EC forges ahead on new transparency rules for tax planning intermediaries22/06/2017 13:37:00
The EC has proposed tough new transparency rules for intermediaries - such as tax advisors, accountants, banks and lawyers - who design and promote tax planning schemes for their clients.
Antitrust: EC fines three car lighting system producers €27m in cartel settlement22/06/2017 13:15:00
The EC has fined Automotive Lighting and Hella a total of €26,744,000 for participating in an automotive lighting cartel, in breach of EU antitrust rules. Valeo was not fined as it revealed the cartel to the Commission. All companies admitted their involvement and agreed to settle.